Curis (CRIS) Gains from Investment Securities (2013 - 2026)

Curis' (CRIS) quarterly Gains from Investment Securities came in at $12.8 million in Q1 2026, up 75897.86% on a QoQ basis from $16786.0 in Q4 2014.

Curis (CRIS) Gains from Investment Securities (2013 - 2026) Analysis & Trends

Curis (CRIS) has 3 years of Gains from Investment Securities data on file, last reported at $12.8 million in Q1 2026.

Quarterly Gains from Investment Securities changed N/A year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (changed N/A YoY) and the FY2014 annual result came in at -$700000.0, up 9.26% from the prior year.
Gains from Investment Securities grew to $12.8 million in Q1 2026, from $16786.0 in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $12.8 million in Q1 2026 to a low of $12.8 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Curis	3.27 Mn	-2.35 Mn	-

Download Data